The sale of DSM-Firmenich’s animal nutrition unit attracts three final bidders, including Nutreco Group, Dutch newspaper reports.
DSM-Firmenich is close to selling its animal nutrition business, with final bids expected from private equity firms CVC, Apollo and Dutch rival Nutreco, Dutch newspaper Financieele Dagblad reported on Sunday, 6 July 2025.
Prospective buyers have until 24 July to submit binding offers, with DSM-Firmenich aiming to finalise the deal in summer 2025, according to the article.
The company announced in 2024 that it planned to divest the Animal Health and Nutrition business by the end of 2025, which would reduce its exposure to earnings volatility in the vitamins segment, while seeking to focus more on fragrances and flavours.
From a strategic perspective, this transaction is part of the company’s portfolio redefinition strategy. Dimitri de Vreeze, CEO of dsm-firmenich, confirmed at the time that they are “on track with the fine-tuning of our portfolio” and that they have initiated their process of exploring transaction options to fully exit the Animal Nutrition and Health business throughout 2025.
DSM-Firmenich is a Swiss company, listed on Euronext Amsterdam, with operations in nearly 60 countries, revenues of over €12 billion and a global workforce of nearly 30,000 employees.
Further reading:
-. Dsm-firmenich’s animal feed unit sale attracts three final bidders, Dutch paper reports (7 July 2025, REUTERS)
-. The multibillion-euro deal between DSM and Firmenich’s animal feed division nears its conclusion. (6 July 2025)
According to Dutch financial newspaper Het Financieele Dagblad BV, three candidates remain for the purchase of DSM-Firmenich’s animal nutrition division… The sale of the DSM division is one of the largest Dutch transactions in the world… DSM-Firmenich previously announced that it wanted to complete the sale process this summer… Nutreco could achieve synergies through the acquisition of the DSM subsidiary.
-. DSM-Firmenich completes the sale of its stake in Feed Enzymes Alliance to Novonesis for €1,500 million (8 June 2025)